THC BioMed Receives Purchase Orders from 30 Dispensaries in the Province of Manitoba

1.8 min readPublished On: September 23rd, 2021By

VANCOUVER, BC – THC BioMed Intl Ltd. announced that it has received orders from 30 dispensaries in the province Manitoba. The Company is also pleased to announce that it has begun shipping THC KISS cannabis edibles and dried cannabis to those dispensaries.

The website thckiss.buzz will be updated to add the Manitoba dispensaries to the list of dispensaries carrying THC BioMed products across Canada.

THC KISS cannabis edibles, are infused with 10 mg of THC KISS extract, a fast acting, full-spectrum, proprietary cannabis extract, invented by THC BioMed.

All products are developed, grown, produced, infused and shipped from our state-of-the-art and fully integrated facility located in beautiful British Columbia, Canada.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed.  In some cases, you can identify forward-looking statements using words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Forward-looking statements in this release are made as of the date of this press release and include that a list of the Manitoba dispensaries will be available on the website and THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

(This information is primarily sourced from THC BioMed.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!